Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$8.22 - $15.13 $1.74 Million - $3.21 Million
212,018 New
212,018 $3.21 Million
Q3 2020

Nov 16, 2020

SELL
$35.13 - $43.62 $12.5 Million - $15.5 Million
-355,366 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$23.66 - $49.53 $3.95 Million - $8.28 Million
-167,114 Reduced 31.98%
355,366 $15.4 Million
Q1 2020

May 15, 2020

SELL
$14.39 - $35.8 $572,103 - $1.42 Million
-39,757 Reduced 7.07%
522,480 $12.1 Million
Q4 2019

Feb 14, 2020

SELL
$23.81 - $33.78 $6.97 Million - $9.89 Million
-292,703 Reduced 34.24%
562,237 $17.6 Million
Q3 2019

Nov 14, 2019

BUY
$21.57 - $31.37 $18.4 Million - $26.8 Million
854,940 New
854,940 $22.3 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $356M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.